Non-Hodgkin's Lymphoma

Antibody Treatment Induced Significant Responses in Patients with Advanced Disease

Published in Cancer Weekly, February 22nd, 2000

Immunomedics, Inc., Morris Plains, New Jersey, announced that a University of Nebraska research team, headed by Julie M. Vose, MD, published an article on the company's radiolabeled LymphoCide product in the January 2000 issue of Leukemia and Lymphoma.

The authors found that the anti-CD22 antibody labeled with iodine-131 had an objective response rate of 33% (complete and partial responses) in a Phase I study of non-Hodgkin's lymphoma patients. Furthermore, 71% of the responders had a complete remission.

Dr. David M. Goldenberg, Immunomedics, stated: "This was a study, concluded in 1997, involving 21 patients given repeated injections of our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-02-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry